The importance of the EGF receptor (EGFR) signaling pathway in the development and progression of nonsmall cell lung carcinomas (NSCLC) is widely recognized. Gene sequencing studies revealed that a majority of tumors responding to EGFR kinase inhibitors harbor activating mutations in the EGFR kinase domain. This underscores the need for novel biomarkers and diagnostic imaging approaches to identify patients who may benefit from particular therapeutic agents and approaches with improved efficacy and safety profiles. To this goal, we We show that PET with [ 18 F]F-PEG6-IPQA in tumor-bearing mice discriminates H3255 NSCLC xenografts expressing L858R mutant EGFR from H441 and PC14 xenografts expressing EGFR or H1975 xenografts with L858R/T790M dual mutation in EGFR kinase domain, which confers resistance to EGFR inhibitors (i.e., gefitinib). The T790M mutation precludes the [ 18 
F]F-PEG6-IPQA from irreversible binding to EGFR. These results suggest that PET with [
18 F]F-PEG6-IPQA could be used for the selection of NSCLC patients for individualized therapy with small molecular inhibitors of EGFR kinase that are currently used in the clinic and have a similar structure (i.e., iressa, gefitinib, and erlotinib).
positron emission tomography | epidermal growth factor receptor | activation mutation L ung cancer is the most common cancer in both men and women, and it is responsible for 1.3 million deaths worldwide annually (1) . In 2009, 219,440 Americans learned they had lung cancer. Nonsmall cell lung carcinoma (NSCLC) represents the majority of lung cancers (2) . NSCLC treatments involving nonspecific, nonselective cytotoxic chemotherapy result in only a modest increase in survival and cause significant toxicity to the patient (3). Therapy with EGF receptor (EGFR) kinase inhibitors results in dramatic antitumor activity in ∼10% of Caucasian patients (young women and nonsmokers) with NSCLC and 30% of patients of East Asian ethnicities (4) (5) (6) (7) (8) (9) (10) (11) . Sequencing of the EGFR gene revealed that most tumors that respond to EGFR kinase inhibitors harbor activating mutations in the EGFR kinase domain (6, 12, 13) . In patients harboring such mutations, the overall response rate is as high as 80% compared with <10% in patients with WT EGFR (6, . Also, the presence of these EGFR kinase mutations is associated with improved progression-free survival and overall survival after therapy with EGFR kinase inhibitors compared with patients with WT EGFR (16, 18, 20, 23, 24, 27) .
The most frequently detected alterations were small deletions in exon 19 (35-45%) that eliminate amino acids 747-750 (LeuArg-Glu-Ala), located around the active site of the kinase, and point mutations in exon 21 that result in the amino acid substitution L858R, a residue located in the activation loop (6) . A secondary T790M mutation is present in ∼50% of cases of NSCLC with acquired resistance to EGFR kinase inhibitors (31) (32) (33) (34) . A recent study showed that the EGFR T790M mutation was associated with significantly shorter progression-free survival compared with patients without detectable T790M before treatment (35) . Thus, activating mutations in EGFR kinase domain and T790M secondary mutation are useful biomarkers for identifying patients who will benefit from or became resistant to therapy with EGFR kinase inhibitors (i.e., gefitinib and erlotinib).
The complexity and limitations of invasive methods of analysis of EGFR mutations prompted the development of novel radiolabeled agents for noninvasive PET imaging, which may help in identification of NSCLC patients who may benefit from EGFR kinase inhibitors. The majority of the previously reported radiolabeled agents for PET imaging of EGFR at the kinase level have been derived from 4-(anilino) quinazoline pharmacophore (36, 37) , which includes the ML series of (46) . Recent PET imaging studies in mice using several PEG-ylated anilinoquinazoline derivatives labeled with 124 I, 18 F, and 11 C failed to show the accumulation of these radiotracers in s.c. tumor xenografts overexpressing WT EGFR (47) . Clinical PET imaging studies with [ 11 C]PD153035 have shown some promise for imaging EGFR expression in NSCLC patients (48) . However, none of the imaging agents reported to date had exhibited selectivity for mutant EGFR kinases that confer sensitivity or resistance to inhibitors that are currently used in the clinic (49) .
Here, we report that the 4- In vitro cell growth of different NSCLC cell lines was differentially inhibited by iressa in a dose-dependent manner. The most sensitive to iressa were the H3255 cells expressing L858R mutant EGFR (IC50 1.8 μm), whereas the H1975 cells expressing both the L858R and T790M EGFR mutations were significantly more resistant (IC50 24.4 μm). The H441 and PC14 cells expressing WT EGFR exhibited significant resistance to iressa (IC50 46.0 and 46.3 μm, respectively).
Differential Expression of EGFR in NSCLC Cell Lines. The levels of total EGFR expression, as measured by ELISA, were similar in H3255 and H441 cells and higher than those in PC14 and H1975 cells (Fig. 1A) . However, the level of phospho-EGFR expression varied less than twofold among the tested cell lines (Fig. 1B) . 18 F]F-PEG6-IPQA continued to increase up for to 1 h and thereafter, reached a plateau at a cells per medium concentration ratio of 400-600 (Fig. 1C) . The magnitude of [
18 F]F-PEG6-IPQA accumulation in H3255 cells was more than 10-fold higher than in H441 cells, despite the twofold lower levels of total EGFR and phospho-EGFR expression in H3255 cells than in H441 cells (Fig. 1 A and B) . The radiotracer washout studies showed significant retention of [ 18 F]F-PEG6-IPQA in H3255 cells (cells per medium concentration ratio of about 400), which accounted for 65% of the total accumulated radioactivity between 60 and 120 min of incubation (Fig. S1 ). In contrast, almost 50% of [ 18 F]F-PEG6-IPQA radioactivity could be washed out from H441 cells, more than 60% could be washed out from PC14 cells, and more than 70% could be washed out from H1975 cells. After washout in PC14 and H1975 cells, the magnitude of [
18 F]F-PEG6-IPQA retention was less than 10 cells/medium concentration ratio. The magnitude of [ 18 F]F-PEG6-IPQA accumulation in all tested cell lines was significantly decreased in the presence of iressa (100 μM/L) in the culture medium (Fig. 1D ). (Fig. 2) . In H441 cells, the level of irreversible binding to the WT EGFR kinase was significantly lower than in H3255 cells. This observation became more evident when comparing the intensity of radioactive bands ( Fig. 2A) and corresponding Western blot bands (Fig. 2B ) of different dilutions of cellular protein extracts. In particular, the 1:10 dilution of H441 extract contained significantly more EGFR protein than the 1:10 diluted extract from H3255 cells; however, the intensity of the radioactive band corresponding to the 1:10 dilution of H3255 cells was significantly greater (at least 1 log order) than that in the 1:10 diluted extract of H441 cells. Autoradiographic detection was more sensitive than immunoblotting and chemoluminescent detection, which was evidenced by the presence of a faint radioactive band in 1:1,000 diluted extracts of H3255 cells, whereas the corresponding Western blot band was not detectable. The covalent binding of [ 18 F]F-PEG6-IPQA to the EGFR kinase domain was barely detectable in undiluted extracts of PC14 cells expressing low levels of WT EGFR and in undiluted extracts of H1975 cells expressing L858R/T790M dual-mutant EGFR. In vitro assays with recombinant WT and mutant EGFR kinases showed ( tumors (2.53 ± 0.15% ID/g) was lower than that in H3255 xenografts, whereas in H1975 (1.27 ± 0.12% ID/g) and PC14 (1.54 ± 0.14% ID/g) tumors, it was significantly lower. Pretreatment with iressa resulted in a fourfold decrease in [ 18 F]F-PEG6-IPQA accumulation in H3255 tumors (to 0.92 ± 0.13% ID/g; P < 0.05) and a threefold decrease in H441 tumors (to 0.78 ± 0.06% ID/g; P < 0.05). There were no statistically significant differences in [ 18 F]F-PEG6-IPQA accumulation in PC14 and H1975 tumor xenografts before and after treatment with iressa (1.17 ± 0.10 and 1.05 ± 0.01% ID/g, respectively).
Discussion
Noninvasive PET/CT imaging of EGFR expression activity and mutation status in NSCLC could aid in the selection of patients for individualized therapy with EGFR kinase inhibitors by complimenting the existing gene sequencing (24) , immunohistochemical (50) , and FISH analyses (51) . More importantly, because repetitive biopsies of multiple tumor lesions in patients with advanced NSCLC are prohibitively traumatic, whole-body noninvasive PET/ CT imaging could provide measures of EGFR expression activity in the individual tumor lesions and estimate treatment-responsive vs. -resistant tumor burden before the initiation of therapy with EGFR inhibitors (i.e., gefitinib and erlotinib); potentially, it could predict the overall outcome.
This study showed significantly increased accumulation of [ 18 F]F-PEG6-IPQA in H3255 cells compared with H441, PC14, and H1975 cells in vitro. Because levels of expression of L858R EGFR in H3255 cells and WT EGFR in H441 cells were similar, the preferential accumulation of [ 18 F]F-PEG6-IPQA in H3255 tumors can be explained, at least in part, by the presence of the L585R activating mutation in the EGFR kinase domain (6, 52, 53) . The L858R mutation dramatically enhances the magnitude of EGFR signaling activity in H3255 cells compared with H441 cells that overexpress WT EGFR (6, 53) and PC14 cells that express WT EGFR at a low level.
Our structure-activity relationship modeling studies (SI Materials and Methods and Fig. S7 ) indicate that the activation status of EGFR kinase seems to be very important for the binding mode of [ 18 F]F-PEG6-IPQA and the formation of a covalent bond with Cys773. Other studies with structurally similar 4-anilinoquinazoline-based reversible inhibitors (gefitinib and erlotinib) have also shown that these compounds had a more than a 20-fold increase in affinity and inhibitory activity for the L858R mutant compared with WT EGFR kinase (54) . A shift in equilibrium to the active state in L858R mutant EGFR kinase and the much stronger alternative binding of [
18 F]F-PEG6-IPQA to the L858R mutant are thought to be the reasons for the more rapid covalent bond formation that leads to faster irreversible entrapment of Although H1975 cells carry the L858R EGFR mutation, the second T790M mutation causes resistance to reversible EGFR inhibitors, such as gefitinib and erlotinib, by interfering with the binding of these inhibitors to the ATP binding site of EGFR kinase (32, 55) . The T790 residue is located at the back of the ATP binding site and is often called the gatekeeper residue (56) . This mechanism is analogous to that resulting from the T315L mutation in Bcr-Abl, which leads to imatinib resistance (57) . In the EGFR-erlotinib structure, the side chain of T790 makes a watermediated hydrogen bond to N3 of the quinazoline. In the EGFRlapatinib structure, the threonine side chain is rotated relative to its position in the erlotinib structure and makes a number of direct and water-mediated hydrogen bonds to the protein. Mutation of this residue to methionine is predicted to sterically block inhibitor binding, because the methionine side chain would occupy part of the same space as the quinazoline ring for both inhibitors (58 (42) that improved water solubility of the 7-oligoPEGylated aminophenylquinazoline analogs will improve the potential of this class of radiolabeled compounds to be used as radiotracers for molecular imaging of EGFR overexpressing tumors.
Another reason for its superior radiotracer characteristics is that [ 18 F]F-PEG6-IPQA is radiolabeled on the 7-(PEG6) side chain, which, on metabolic cleavage from the quinazoline core, is rapidly eliminated through renal clearance, as evidenced by the early appearance of radioactivity in the bladder. On metabolic degradation of [ 18 F]F-PEG6-IPQA and similar 7-(PEG6) analogs, the 6-acrylamide aminophenyl-quinazoline pharmacophore is known to bind to both inactive and activated EGFR kinase and does not discriminate between the WT and active mutant EGFR kinases. Therefore, the aminophenyl moiety of this class of compounds is not suitable for radiolabeling, because it would render compounds that, on metabolic cleavage of 7-(PEG6) moiety, would have much higher lipophilicity and longer half-time circulation and would not adequately discriminate between the WT and L858R active mutant EGFR kinase. In contrast, [ 
Materials and Methods

The [
18 F]F-PEG6-IPQA was prepared in high specific activity and high purity following the method described elsewhere (63) . Four NSCLC cell lines expressing different levels of WT and active mutant EGFR and different sensitivity iressa were used: (i) H441 (WT EGFR; resistant) (6, 53), (ii) PC14 (WT EGFR; resistant) (64-66), (iii) H3255 (mutant L858R EGFR; sensitive) (6, 52, 53) , and (iv) H1975 (L858R, T790M double-mutant EGFR; resistant) (32, 55) . In vitro radiotracer uptake and washout studies were performed in monolayer cultures of these different tumor cell lines as previously described (43, 67 Cells were kept in the log phase of proliferative activity. The sensitivity of tumor cells to iressa in the culture medium was assessed by incubating the cells in 96-well plates (Nunc) for 2 d in the presence of different concentrations of iressa and measuring the degree of tumor cell growth inhibition using the water-soluble tetrazolium (WST) colorimetric assay (Cat #TA KMK400; Fisher Scientific). Absorbance was measured at 450 nm using the Safire microplate spectrophotometer (Tecan). The data were analyzed using the software package Prizm v.4 (GraphPad Software, Inc).
ELISA for EGF Receptor. The cells were grown until 50% confluent and then harvested by scraping. Cells were pelleted, frozen on dry ice, and then thawed and lysed in a buffer (500 μL/100 mg cells) containing 20 mM Tris·HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1 mM NaF, Triton X-100 1%, and protease inhibitor mixture 10 μL/mL (all reagents from Sigma-Aldrich) for 1 h at 4°C. The lysate was then sonicated 3 × 10 s on ice and cleared by 14,000 × g centrifugation at 4°C for 10 min. Protein concentration in the supernatant was measured by BCA Protein Assay (Thermo Scientific). Equal amounts of protein (in 100 μL volume) were added into a high binding capacity 96-well plate (Corning) and incubated for 1 h at room temperature (RT). Then, the lysate was removed, and 300 μL protein-free blocking buffer (Thermo Scientific) were added to each well for 1 h at room temperature; then, the wells were washed and incubated with antibodies against C terminus or phoshpo-tyrosine 845 of EGF receptor (EGFR; Santa Cruz Biotechnology). Incubation was terminated by washing the wells five times with PBS. HRP-conjugated secondary antibodies (Santa Cruz Biotechnology) were added for 1 h, and then, the wells were washed five times with phosphate buffer saline tween-20 (PBS-T). Colorimetric reaction was initiated by adding Ultra tetramethylbenzidine (TMB)-ELISA substrate (Thermo Scientific) and stopped by adding 2 M H 2 SO 4 . Absorbance was measured at 450 nm using the Safire microplate spectrophotometer (Tecan). The data were analyzed using the software package Prizm v.4 (GraphPad Software, Inc). F]F-PEG6-IPQA at 0.37 MBq/mL. Next, the cells were washed with PBS, harvested in PBS by scraping, and pelleted by centrifugation at 400 × g for 5 min; the supernatant was removed, and the cell pellet was frozen on dry ice. Then, the cell pellet was thawed and lysed in the same lysis buffer as described above (200 μL/100 mg cells) for 1 h at 4°C. The lysate was sonicated at 3 × 10 s on ice and cleared by centrifugation (14,000 rpm) at 4°C for 10 min. The supernatant was denatured by heating at 70°C with lithium dodecyl sulfate (LDS) sample buffer (Invitrogen) and separated by SDS/polyacrylamide gel electrophoresis using precast 4-12% Tris·HCl gel cassettes (Invitrogen). After transferring proteins onto a nitrocellulose membrane using a semidry electroblotting device (Invitrogen), the membrane was exposed to HyBlot CL autoradiography film (Denville Scientific) for 12 h to visualize the [ 18 F]-labeled protein bands. Then, the membrane was immunostained with a goat polyclonal antibody to C terminus of EGFR (Santa Cruz Biotechnology) and visualized using the ECL kit (Bio-Rad). The colocalization of [ 18 F]-labeled protein bands in the autoradiogram with protein bands stained with anti-EGFR antibody was assessed using the image analysis software MCID Analysis Rev.7.0 (InterFocus Imaging Ltd).
EGFR Kinase Assay. Biotinylated (Gly) 4 -Tyr peptide (Upstate Biotechnologies), 0.1 mg/mL in 100 mM sodium bicarbonate buffer (pH 8.0), was incubated for 2 h in streptavidine-coated 96-well plates (Costar); nonspecific binding sites were blocked by incubation with 300 μL 3% BSA for 1 h. Tyrosine phosphorylation was initiated by adding to each well 50 ng recombinant WT EGFR, L858R EGFR, or L858R/T790M EGFR (Upstate Biotechnologies) in 100 μL assay buffer (20 mM Tris, pH 7.4, 10 mM MgCl 2 , 1 mM MnCl 2 , 0.2 mM ATP, 1 mM dithiothretiol, 25 mM β-glycerol phosphate, 1 mM sodium orthovanadate, 5 mM EGTA) (Sigma-Aldrich) and incubating for 30 min at 37°C. Different concentrations of F-PEG6-IPQA were added simultaneously with the enzyme to assess dose-dependent inhibitory activity against different EGFRs. Phospho-tyrosine residues were detected by incubation with antiphosphotyrosine HRP-conjugated antibodies for 1 h at room temperature. Colorimetry was initiated by adding tetramethylbenzedine (Pierce Biotechnology), and 10 min later, the absorbance at 450 nm was measured using microplate reader Safire (Tecan). Washing with PBS (5 × 300 μL) was performed after each step. PET Image Acquisition and Data Analysis. The mice were gasanesthetized (2% isoflurane per 98% oxygen mixture) and injected with [
18 F]F-PEG6-IPQA (7.4 MBq/150 μL) through the tail vein. Whole-body dynamic PET images were acquired in a 2D mode for 2 h on a small-animal PET/CT scanner INVEON (Siemens) followed by a static scan at 3 h postradiotracer administration. Images were reconstructed using the ordered subset expectation maximization (OSEM) algorithm. The PET images were corrected for attenuation using CT imaging data using the manufacturer's software. Regional radioactivity concentration (KBq per milliliter) of 
where C Tissue is the radioactivity concentration in the tissue of interest (i.e., tumor) and C p is the radioactivity concentration in plasma. The slope of the Patlak plot represents the unidirectional influx rate constant K i , whereas the intercept V equals V0 + vB with the distribution volume V0 of the reversible compartment and the fractional blood volume vB. Also, the dynamic PET imaging data were analyzed using Logan's model-independent graphical analysis (3) to assess whether [
18 F]F-PEG6-IPQA PET/CT could be used to detect differences in expression of active mutant EGFR in tumors. The ratio of integrated radioactivity concentration in tumors over time normalized by the radioactivity concentration at a given time point in tumor radioactivity concentration was set as the y axis. The ratio of integrated reference tissue radioactivity concentration over time normalized by tumor radioactivity concentration was set as the x axis of a Logan plot. The muscle was used as reference tissue, because it has low EGFR expression. The slope of the linear portion of the Logan plot is the distribution volume ratio (DVR). If metabolite-corrected plasma TACs are not available, the plasma TAC can be replaced with reference region TAC, C r (t). Then, the slope of the linear portion of the lot is calculated as (Eq. S2)
The binding potential (BP) can be calculated as (Eq. S3)
Quantitative Autoradiography. After PET imaging, the mice were killed, and the tumors were extracted rapidly, frozen, and embedded in the M1 mounting medium (Shandon-Lipshaw). Serial 20-μm-thick coronal frozen sections were cut at −13°C using a CM3050S cryomicrotome (Leica). Tissue sections were thawmounted on poly-A lysine-coated glass slides and heat-fixed for 5 min at 65°C on a slide warmer (Fischer Scientific). For quantitative autoradiography (QAR), one set of tissue sections was exposed for 6-8 h to the BAS SR-2040 phosphor imaging plate (Fujifilm) along with a set of 20-μm autoradiographic standards of known 18 F radioactivity concentration freshly prepared using calf liver homogenate. Images were acquired using a phosphorimager system FLA5100 (Fujifilm). Using the known radioactivity concentration in the standards and the injected dose, the autoradiographic images were converted to color-coded parametric images of percent ID per gram tissue using image analysis software MCID Elite 7.0 (InterFocus Imaging Ltd). Another set of tissue sections adjacent to those used for QAR was stained with H&E.
In Silico Modeling of [ 18 F]PEG6-IPQA Binding to EGFR. Methods. Ligand docking studies were carried out using Molecular Operating Environment (MOE) 2008.10 software (Chemical Computing Group). Structures of the cytoplasmic kinase domain of EGFR used for docking experiments with PEG6-IPQA were downloaded from the Protein Data Bank. The model for the inactive conformation of EGFR was derived from the lapatinib-bound structure 1XKK, and the gefitinib-bound L858R structure 2ITZ was used as the active conformation of the EGFR kinase domain for the docking configuration studies. The coordinates for the alternate binding mode structure were kindly provided by Michael Eck (Harvard Medical School, Boston, MA) (4). The structure of the double L858R/T790M mutant domain was constructed by replacing the side chain of T790 with that of methionine in 2ITZ. Contact constraints were removed by minimizing the structure through a steep gradient using the AMBER99 force field in the energy minimize function of MOE.
Before docking, the structures were protonated using the using the Protonate3D command of MOE. The active site was broadly defined based on residue proximity (≤4.5 Å) to the binding conformation of both ATP and gefitinib to include the probability of docking in either conformation, and it was graphically delineated with Gaussian contact surfaces. The water molecules in the vicinity of the active site were retained. The structure of PEG6-IPQA was constructed by modifying the structure of gefitinib using the builder feature of MOE, adding hydrogen atoms, and minimizing the final structure using the steepest descent algorithms. Rigid receptor-flexible ligand docking was performed using the dock simulation feature of MOE. Ligands were docked into the active and inactive EGFR kinase domain structures. The triangle matcher placement method was used to generate docking poses, and each conformation was scored based on the London ΔG scoring function that estimates the free energy of binding (kilocalories per mole). Results. Docking results have shown that F-PEG6-IPQA can bind to both inactive and active L858R mutant forms of the EGFR kinase domain, adopting a conformation similar to gefitinib. However, the binding affinity of F-PEG6-IPQA to the active L858R mutant EGFR kinase was considerably higher, as indicated by the calculated free energy of binding of −22.8 and −16.1 kcal/mol for the active and inactive conformations, respectively (Fig. S7 A and B) . This may partly be because of the more favorable van der Waals interactions with the 3-iodo aniline group in the back of the ATP binding pocket present only in the active conformation. Higher affinity of F-PEG6-IPQA to the active L858R mutant EGFR may also be attributed to an alternate binding mode similar to that reported by Yun et al. (4) for gefitinib in the L858R mutant structure. Such an alternate binding mode results in a higher gefitinib binding affinity, where the aniline ring of the inhibitor is rotated 180°, positioning the metachlorine at close proximity to the side chain of Asp855 to form a halogen bond. Such binding mode may be preferred in active mutant variants but cannot occur in the inactive WT EGFR kinase, because the required reorientation of the Asp855 is hindered by the presence of leucine at position 858. Similarly, we have found that F-PEG6-IPQA can dock in this alternate mode at a higher binding affinity (−23 kcal/mol), where the iodoaniline group is rotated 180°to interact with Asp855 (Fig. S7C) . F-PEG6-IPQA was also able to dock into the L858R/T790M EGFR kinase in correct binding conformation. However, the calculated binding free energy of −16.9 kcal/mol was higher than that observed for the L858R mutant, indicating a lower binding affinity (Fig. S7D) .
In silico modeling also revealed potential interactions of F-PEG6-IPQA with other EGFR active site residues. The docking conformation of F-PEG6-IPQA illustrates its covalent bonding potential with Cys797 of the active site (Fig. S7B) . The acrylamide moiety of the F-PEG6-IPQA rests less that 1.5 Å from the ter-minal sulfhydryl group of Cys797 to conceivably form a thiol bond. The hydrophilic PEG6 chain of the molecule is externally localized where it can interact with the outer hydrophilic surface of the binding pocket. Multiple docking iterations show that the PEG6 chain can assume many different configurations because of the rotational freedom around the single bonds in the chain. Most of those configurations, however, help to orient the rest of the molecule in the binding site, which results in a closer positioning of the acrylamide moiety in relation to the Cys797 and facilitates the alkylation reaction and covalent bond formation. . In silico docking of F-PEG6-IPQA with the WT (A), active L858R mutant (B and C), and TKI-resistant L858R/T790M double-mutant EGFR kinase. F-PEG6-IPQA can bind to both active WT (A) and L858R mutant (B) forms of the EGFR kinase domain in a conformation similar to gefitinib (green structure). This conformation places the acrylamide moiety of F-PEG6-IPQA in close proximity to the sulfhydryl group of Cys797 (orange arrow). F-PEG6-IPQA can also bind to the L858R mutant in an alternate conformation where the aniline ring of the substrate is rotated 180°, positioning the metaiodine (yellow arrow) at close proximity to the side chain of Asp855 (C). F-PEG6-IPQA can also dock into the active site of the L858R/T790M double mutant in the correct conformation (D), albeit with a higher calculated binding energy, which indicates a weaker binding affinity.
